• Andrew A J, Miyagi E, Strebel K. Differential effects of human immunodeficiency virus type 1 vpu on the stability of bst-2/tetherin[J]. J Virol, 2010, 85(6): 2611-2619.

  • Douglas J L, Viswanathan K, McCarroll M N. Vpu directs the degradation of the human immunodeficiency virus restriction factor bst-2/tetherin via a {beta}trcp-dependent mechanism[J]. J Virol, 2009, 83(16): 7931-7947. doi: 10.1128/JVI.00242-09

  • Goto T, Kennel S J, Abe M. A novel membrane antigen selectively expressed on terminally differentiated human b cells[J]. Blood, 1994, 84(6): 1922-1930.

  • Gupta R K, Mlcochova P, Pelchen-Matthews A. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/bst-2/cd317 by intracellular sequestration[J]. Proc Natl Acad Sci U S A, 2009, 106(49): 20889-20894. doi: 10.1073/pnas.0907075106

  • Hauser H, Lopez L A, Yang S J. Hiv-1 vpu and hiv-2 env counteract bst-2/tetherin by sequestration in a perinuclear compartment[J]. Retrovirology, 2010, 7(): 51-. doi: 10.1186/1742-4690-7-51

  • Ishikawa J, Kaisho T, Tomizawa H. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, bst2, that may be involved in pre-b-cell growth[J]. Genomics, 1995, 26(3): 527-534. doi: 10.1016/0888-7543(95)80171-H

  • Klimkait T, Strebel K, Hoggan M D. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release[J]. J Virol, 1990, 64(2): 621-629.

  • Kong X, West J T, Zhang H. The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses[J]. J Virol, 2008, 82(23): 11609-11618. doi: 10.1128/JVI.00952-08

  • Kupzig S, Korolchuk V, Rollason R. Bst-2/hm1.24 is a raft-associated apical membrane protein with an unusual topology[J]. Traffic, 2003, 4(10): 694-709. doi: 10.1034/j.1600-0854.2003.00129.x

  • Le Tortorec A, Willey S, Neil S J. Antiviral inhibition of enveloped virus release by tetherin/bst-2: Action and counteraction[J]. Viruses, 2011, 3(5): 520-540.

  • Liu C, Shi Y J, Xuan C h. Establishment of an in vitro protein modification system with antiserum against ubiquitin-like modifier bisg15[J]. Chin J Biochem Mol Biol, 2008, 24(1): 30-34.

  • Liu C, Chang R, Yao X. Isg15 expression in response to double-stranded rna or lps in cultured fetal bovine lung (fbl) cells[J]. Vet Res Commun, 2009, 33(7): 723-733. doi: 10.1007/s11259-009-9221-8

  • Malim M H, Emerman M. HIV-1 accessory proteins--ensuring viral survival in a hostile environment[J]. Cell Host Microb, 2008, 3(6): 388-398. doi: 10.1016/j.chom.2008.04.008

  • Miller A D, Chen F. Retrovirus packaging cells based on 10a1 murine leukemia virus for production of vectors that use multiple receptors for cell entry[J]. J Virol, 1996, 70(8): 5564-5571.

  • Naito Y, Ui-Tei K, Nishikawa T. Sivirus: Web-based antiviral sirna design software for highly divergent viral sequences[J]. Nucleic Acids Res, 2006, 34(Web Server issue): W448-450.

  • Neil S J, Zang T, Bieniasz P D. Tetherin inhibits retrovirus release and is antagonized by hiv-1 vpu[J]. Nature, 2008, 451(7177): 425-430. doi: 10.1038/nature06553

  • Nguyen D H, Hildreth J E. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts[J]. J Virol, 2000, 74(7): 3264-3272. doi: 10.1128/JVI.74.7.3264-3272.2000

  • Platt E J, Bilska M, Kozak S L. Evidence that ecotropic murine leukemia virus contamination in tzm-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1[J]. J Virol, 2009, 83(16): 8289-8292. doi: 10.1128/JVI.00709-09

  • Reinke S O, Bayer M, Berger M. Analysis of cell surface n-glycosylation of the human embryonic kidney 293t cell line[J]. J Carbohydr Chem, 2011, 30(4-6): 218-232. doi: 10.1080/07328303.2011.600489

  • Salmon P, Trono D. 2006. Design and production of human immunodeficiency virus-derived vectors, In: Cell biology: A laboratory handbook. Celis J E, ed. , Third Edition: Elsevier Inc. Volume 1, pp425-434.

  • Skasko M, Wang Y, Tian Y. HIV-1 vpu protein antagonizes innate restriction factor bst-2 via lipid-embedded helix-helix interactions[J]. J Biol Chem, 2011, 287(1): 58-67.

  • Terwilliger E F, Cohen E A, Lu Y C. Functional role of human immunodeficiency virus type 1 vpu[J]. Proc Natl Acad Sci U S A, 1989, 86(13): 5163-5167. doi: 10.1073/pnas.86.13.5163

  • Tokarev A, Skasko M, Fitzpatrick K. Antiviral activity of the interferon-induced cellular protein bst-2/tetherin[J]. AIDS Res Hum Retroviruses, 2009, 25(12): 1197-1210. doi: 10.1089/aid.2009.0253

  • Van Damme N, Goff D, Katsura C. The interferon-induced protein bst-2 restricts hiv-1 release and is downregulated from the cell surface by the viral vpu protein[J]. Cell Host Microbe, 2008, 3(4): 245-252. doi: 10.1016/j.chom.2008.03.001